Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
La mesure figure dans le projet de loi de simplification des normes applicables aux collectivités. Elle vise à combler le vide juridique laissé par la réforme de la haute fonction publique et la ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results